Discovery of a selective inhibitor for the YEATS domains of ENL/AF9 by Christott, T, Bennett, J, Coxon, C, Monteiro, O, Giroud, C, Beke, V, Felce, S, Gamble, V, Gileadi, C, Poda, G, Al-Awar, R, Farnie, G, Fedorov, O

Bromo-deaza-SAH: a potent and selective DOT1L inhibitor. by Yu, W, Smil, D, Li, F, Tempel, W, Fedorov, O, Nguyen, K, Bolshan, Y, Al-Awar, R, Knapp, S, Arrowsmith, C, Vedadi, M, Brown, P, Schapira, M

Bromo-deaza-SAH: A potent and selective DOT1L inhibitor by Yu, W, Smil, D, Li, F, Tempel, W, Fedorov, O, Nguyen, K, Bolshan, Y, Al-Awar, R, Knapp, S, Arrowsmith, C, Vedadi, M, Brown, P, Schapira, M

Targeting ALK2: an open science approach to developing therapeutics for the treatment of diffuse intrinsic pontine glioma by Ensan, D, Smil, D, Zepeda-Velázquez, CA, Panagopoulos, D, Wong, JF, Williams, EP, Adamson, R, Bullock, AN, Kiyota, T, Aman, A, Roberts, OG, Edwards, AM, O'Meara, JA, Isaac, MB, Al-Awar, R

Discovery of conformationally constrained ALK2 inhibitors by González-Álvarez, H, Ensan, D, Xin, T, Wong, JF, Zepeda-Velázquez, CA, Cros, J, Sweeney, MN, Hoffer, L, Kiyota, T, Wilson, BJ, Aman, A, Roberts, O, Isaac, MB, Bullock, AN, Smil, D, Al-Awar, R

Leveraging an open science drug discovery model to develop CNS penetrant ALK2 inhibitors for the treatment of diffuse intrinsic pontine glioma by Smil, D, Wong, JF, Williams, E, Adamson, R, Howarth, A, McLeod, D, Mamai, A, Kim, S, Wilson, B, Kiyota, T, Aman, A, Owen, J, Poda, G, Horiuchi, K, Kuznetsova, E, Ma, H, Hamblin, JN, Cramp, S, Roberts, O, Edwards, AM, Uehling, D, Al-awar, R, Bullock, AN, O'Meara, J, Isaac, M

Discovery of an MLLT1/3 YEATS domain chemical probe by Moustakim, M, Christott, T, Monteiro, O, Bennett, J, Giroud, C, Ward, J, Rogers, C, Smith, P, Panagakou, I, Saez, L, Felce, S, Gamble, V, Gileadi, C, Halidi, N, Heidenreich, D, Chaikuad, A, Knapp, S, Huber, K, Farnie, G, Heer, J, Manevski, N, Poda, G, Al-Awar, R, Dixon, D, Fedorov, O, Brennan, P